Lancet Oncology

Article	Citations
Use of artificial intelligence to enhance detection of nodal metastases	801
The future of precise cancer chronotherapeutics	777
SABR for operable stage I non-small-cell lung cancer: comparison to surgery	696
Patients with cancer in Louisiana denied fertility preservation cover	530
Innovation in gynaecological cancer: highlighting global disparities	528
Survivorship after neoadjuvant chemotherapy	491
Combination immunotherapy in chemotherapy in gastric cancer	471
Psychosocial impact associated with a multicancer early detection test (PATHFINDER): a prospective, multicentre, cohort study	460
Driving two chimeric antigen receptors (CARs) in a row to reduce antigen escape in B-cell acute lymphocytic leukaemia	429
US FDA proposes stronger laboratory test oversight	424
Correction to Lancet Oncol 2022; 23: 1124–26	406
Correction to Lancet Oncol 2021; 22: 309–20	381
Medical treatment for active breast cancer brain metastases	366
COVID-19 pandemic causes cervical cancer screening crisis	366
Enhancing equity and long-term impact assessments in radiotherapy environmental studies	358
IVLBCL mimicking VEXAS syndrome	339
Development of a conceptual framework for an electronic patient-reported outcome (ePRO) system measuring symptoms and impacts of CAR T-cell therapies in patients with haematological malignancies	331
The silent malignant mesothelioma epidemic: a call to action	315
Crossing survival curves of KEYNOTE-177 illustrate the rationale behind combining immune checkpoint inhibition with chemotherapy	313
The GLOW trial in chronic lymphocytic leukaemia	302
Predicting outcomes after 177Lu-PSMA therapy in castration-resistant prostate cancer	301
Dual therapy in metastatic castration-resistant prostate cancer	298
Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in advanced ovarian cancer – Authors' reply	291
Non-invasive DNA methylation-based testing for the diagnosis of endometrial cancer	290
A new generation of comprehensive precision oncology trials	286

Correction to Lancet Oncol 2021; 22: 1081–92	281
Italy to pass law on the right to be forgotten for cancer survivors	276
Patient-reported outcomes from the MIRASOL trial evaluating mirvetuximab soravtansine versus chemotherapy in patients with folate receptor α-positive, platinum-resistant ovarian cancer: a randomised,	276
Combining enzalutamide and [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer	274
Olanzapine for chemotherapy-induced nausea and vomiting control	274
Palliative radiotherapy for hepatic cancer pain	270
Concern for cancer drugs in USA–EU tariff war	266
Sex disparity in childhood cancer in India: a multi-centre, individual patient data analysis	266
International Radiation Oncology societies Network (IRON): a unified voice in addressing global cancer challenges	261
Clinical and biological landscape of constitutional mismatch-repair deficiency syndrome: an International Replication Repair Deficiency Consortium cohort study	256
Study bolsters concerns about US FDA accelerated drug approvals	255
Precancerous cervical lesions caused by non-vaccine-preventable HPV types after vaccination with the bivalent AS04-adjuvanted HPV vaccine: an analysis of the long-term follow-up study from the randomi	252
Radiotherapy plus immune checkpoint blockade in PD(L)-1-resistant metastatic NSCLC	251
US Surgeon General calls for cancer warning labels on alcohol	249
Health-related quality of life and pain outcomes with [177Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a mult	247
Discontinuation versus continuation of imatinib in patients with advanced gastrointestinal stromal tumours (BFR14): exploratory long-term follow-up of an open-label, multicentre, randomised, phase 3 t	247
Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial	240
Digital breast tomosynthesis plus synthesised mammography versus digital screening mammography for the detection of invasive breast cancer (TOSYMA): a multicentre, open-label, randomised, controlled,	238
Impact of COVID-19 on cancer care in India: a cohort study	234
Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1–2, open-label, multicohort trial	228
Multinational Association of Supportive Care in Cancer (MASCC) clinical practice guidelines for the prevention and management of acute radiation dermatitis: international Delphi consensus-based recomm	225
Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial	222
Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma under	221
Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery	221
Pyrotinib plus capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases (PERMEATE): a multicentre, single-arm, two-cohort, phase 2 trial	219
Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase	208
Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study	206
Exploring the link between cancer policies and cancer survival: a comparison of International Cancer Benchmarking Partnership countries	205
Antibody–drug conjugates in acute myeloid leukaemia: more research needed	201
Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial	201
CAR T cells for the long run in aggressive B-cell lymphoma	200
Precision medicine for children with cancer	200
Focus where it matters: turning insights into advocacy	197
Radiotherapy and conflict: from disruption to expansion and hope	189
Effect of glycated haemoglobin A1c on the survival of patients with oral squamous cell carcinoma and diabetes: a multicentre, retrospective, database cohort study	188
Decentralised, point-of-care CAR-T for multiple myeloma	188
A biobank perspective on use of tissue samples donated by trial participants	187
The challenges of cancer care for the LGBTQ+ community	183
Dobbs v Jackson and fertility preservation among adolescents and young adults with cancer	181
From the European Medicines Agency to Project Orbis: new activities and challenges to facilitate UK oncology drug approval following Brexit	180
Endocrinopathies induced by immune checkpoint inhibitors: the need for clear endocrine diagnosis	177
Common Sense Oncology: including everyone	175
A growing vulvar mass in a post-menopausal woman	175
Retroperitoneal fibrosis: carcinoid recurrence or histiocytosis?	174
Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk, early breast cancer – Authors' reply	172
Gestational trophoblastic neoplasia: one size does not fit all – Authors' reply	172
Essential anticancer medicines for children: defining what matters most for Europe	171
Greater price transparency needed for thyroid cancer treatment among US cancer centres	170
Lung cancer rates highest among British Bangladeshi men	167
Importance of clinical research for the UK's 10-year cancer plan	165

The socioeconomic impact of cancer on patients and their relatives: Organisation of European Cancer Institutes task force consensus recommendations on conceptual framework, taxonomy, and research dire	163
Estimating the impact of the COVID-19 pandemic on diagnosis and survival of five cancers in Chile from 2020 to 2030: a simulation-based analysis	162
Balancing clinical benefit and social value: challenges in HTA assessments	160
Alcohol and the global burden of cancer: what are we missing?	160
Adjuvant therapy in stage IIIA melanoma - Authors' reply	158
Use of PROMISE criteria on PSMA-PET for prediction of overall survival in prostate cancer	155
First-line talazoparib plus enzalutamide versus placebo plus enzalutamide in men with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: patient-repo	152
Sequential CD19 and CD22 chimeric antigen receptor T-cell therapy for childhood refractory or relapsed B-cell acute lymphocytic leukaemia: a single-arm, phase 2 study	152
Treatment guideline concordance, initiation, and abandonment in patients with non-metastatic breast cancer from the African Breast Cancer–Disparities in Outcomes (ABC-DO) cohort in sub-Saharan Africa:	152
Dose recommendations for anticancer drugs in patients with renal or hepatic impairment: an update	151
Development and validation of a novel model to predict recurrence-free survival and melanoma-specific survival after sentinel lymph node biopsy in patients with melanoma: an international, retrospecti	150
Recommendations on the use of item libraries for patient-reported outcome measurement in oncology trials: findings from an international, multidisciplinary working group	150
ICGC-ARGO precision medicine: an update on targeted therapy based on longitudinal analysis of tumour heterogeneity and evolution in colorectal cancer	148
Lebanon faces critical shortage of drugs	147
Cancer on the agenda during IAEA Director General's visit to Chile	145
Shortages of essential medications for children with cancer in Colombia	143
Radiotherapy with genomic-adjusted radiation dose	143
Radiotherapy with genomic-adjusted radiation dose	143
GDPR obstructs cancer research data sharing	142
Dobbs v Jackson and access to fertility care among newly diagnosed adolescents and young adults with cancer in the USA	140
Daratumumab maintenance in patients with myeloma	138
Challenges and prospects for cancer treatment in prison settings	137
Correction to Lancet Oncol 2023; 24: e242	137
Correction to Lancet Oncol 2020; 21: 699–709	136
2022 ASTRO annual meeting	136
Clearing the radiotherapy backlog: innovation to pave the way	134
Mantle cell lymphoma: is it time for risk-adapted treatment?	134
Syrian cancer patients regain treatment access in Türkiye	134
Carcinogenicity of hydrochlorothiazide, voriconazole, and tacrolimus	133
Performance of the WID-qEC test versus sonography to detect uterine cancers in women with abnormal uterine bleeding (EPI-SURE): a prospective, consecutive observational cohort study in the UK	130
Assessment of endpoint definitions in recurrent and metastatic mucosal head and neck squamous cell carcinoma trials: Head and Neck Cancer International Group consensus recommendations	130
Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial	127
Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup	127
Comparative effectiveness and risk of preterm birth of local treatments for cervical intraepithelial neoplasia and stage IA1 cervical cancer: a systematic review and network meta-analysis	127
WHO reports health service disruptions due to suspensions of aid	124
Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial	124
Addition of ramucirumab or merestinib to standard first-line chemotherapy for locally advanced or metastatic biliary tract cancer: a randomised, double-blind, multicentre, phase 2 study	124
Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, ra	124
India rolls out HPV vaccination	123
Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, randomised, double-blind, placebo-controlled, phase 1b/2 trial	123
Deep-learning-based reconstruction of undersampled MRI to reduce scan times: a multicentre, retrospective, cohort study	123
[89Zr]Zr-girentuximab for PET–CT imaging of clear-cell renal cell carcinoma: a prospective, open-label, multicentre, phase 3 trial	120
ROAR trial: which treatment is effective after progression?	120
Mozambique takes on cancer burden challenges	119
Endometrial cancer: the individual approach	118
Secondary cytoreduction for relapsed ovarian cancer	115
A step closer to the use of [177Lu]Lu-PSMA-617 in metastatic hormone-sensitive prostate cancer	113
Correction to Lancet Oncol 2023; 24: 1181–95	111
Immunogenicity and safety of a new quadrivalent HPV vaccine in girls and boys aged 9–14 years versus an established quadrivalent HPV vaccine in women aged 15–26 years in India: a randomised, active-co	110
Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (OPTIMIZE-1): a single-arm, multicentre phase 1b/2 study	109
Olanzapine for chemotherapy-induced nausea and vomiting control – Authors’ reply	109
Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: a randomised, double-blind, phase 2 trial	108
Internationally trained doctors in the USA	107
Moderately hypofractionated radiotherapy for prostate cancer in an era of SBRT and focal boosting	107
The prognosis of patients with small cell carcinoma of the cervix: a retrospective study of the SEER database and a Chinese multicentre registry	106
Changes in cancer diagnoses and stage distribution during the first year of the COVID-19 pandemic in the USA: a cross-sectional nationwide assessment	106
Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label,	105
Primary lung tumour stereotactic body radiotherapy followed by concurrent mediastinal chemoradiotherapy and adjuvant immunotherapy for locally advanced non-small-cell lung cancer: a multicentre, singl	105
AACR Annual Meeting 2023	103
6-month or 12-month adjuvant trastuzumab regimen for HER2-positive breast cancer? Decision-making in a resource-limited setting	102
Correction to Lancet Oncol 2024; 25: e126–35	101
Correction to Lancet Oncol 2021; 22: 1497–98	101
Shortage of cancer drugs in Mexico	100
Tumour response heterogeneity as a powerful independent predictor of treatment outcome in advanced lung adenocarcinoma: a retrospective analysis	98
Transforming cancer: behind the scenes at the Crick Institute	97
Radical cystectomy vs trimodality therapy for muscle-invasive bladder cancer: further extensive evaluation needed – Authors' reply	97
Pancytopenia associated with bone marrow infiltration from late relapse of neuroblastoma	96
Managing immune checkpoint inhibition in transplant recipients	96
The thin border between individual and collective ethics: the downside of GDPR	96
Second-line FOLFOX chemotherapy for advanced biliary tract cancer	95
Study of the Veterans Affairs Health Care System highlights the impact of COVID-19 on cancer diagnoses in the USA	95
Promoting cancer prevention through World Cancer Day in Nigeria	93
On a precipice: the UK's broken health-care system	93
Are immune checkpoint combination therapies for intermediate and poor risk renal cell carcinoma better than immune checkpoint inhibitors combined with kinase inhibitors?	92
Medical debt of people with cancer in the USA	91
Stereotactic ablative radiotherapy for primary kidney cancer – Authors' reply	90
Placenta can provide new insights on the genetics of cancer	89
Pembrolizumab monotherapy for advanced chordoma – Authors' reply	86
Standardised definitions and diagnostic criteria for extranodal extension detected on histopathological examination in head and neck cancer: Head and Neck Cancer International Group consensus recommen	86
Is upfront full molecular profiling needed in all patients with colorectal cancer in daily practice?	83

A manifesto for improving cancer detection: four key considerations when implementing innovations across the interface of primary and secondary care	83
Full-dose SBRT for the primary tumour in stage III NSCLC: a promising and safe way to selective dose escalation?	82
South Africa's new tobacco and e-cigarette control bill	82
Screening for breast cancer brain metastases	81
Dosimetry in radionuclide therapy: the clinical role of measuring radiation dose	81
Adaptive radiotherapy (up to 74 Gy) or standard radiotherapy (66 Gy) for patients with stage III non-small-cell lung cancer, according to [18F]FDG-PET tumour residual uptake at 42 Gy (RTEP7–IFCT-1402)	80
Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (Lung ART, IFCT 0503): an open-lab	79
Rucaparib for recurrent ovarian cancer with BRCA1 and BRCA2 mutations – Authors' reply	79
Using patient-reported outcomes and health-related quality of life data in regulatory decisions on cancer treatment: highlights from an EMA-EORTC workshop	79
Towards establishing the standard of care for second-line therapy in advanced biliary tract cancer	78
Stereotactic radiosurgery for patients with small-cell lung cancer brain metastases	78
Second-line FOLFOX chemotherapy for advanced biliary tract cancer	78
Unresolved questions regarding the promise of the TPEx regimen	76
Code of practice needed for samples donated by trial participants – Sponsor's reply	76
Intensifying neoadjuvant treatment in locally advanced rectal cancer – Authors' reply	74
Poor cancer care in Zimbabwe	73
A novel alternative to cytotoxic chemotherapy for gestational trophoblastic disease	73
Quality control and childhood cancer medicines	72
Pilot cancer programmes in Côte d'Ivoire, Kenya, and Zimbabwe	72
Correction to Lancet Oncol 2022; 23: 1297–307	69
Incorporating absolute effects to enrich interpretation of findings from meta-analyses – Authors' reply	68
Correction to Lancet Oncol 2023; 24: e472–518	68
CALLA trial: immunotherapy in locally advanced cervical cancer – Authors' reply	68
Correction to Lancet Oncol 2016; 17: 484–95	68
Correction to Lancet Oncol 2023; 24: 91–106	68
Rezvilutamide for metastatic hormone-sensitive prostate cancer – Authors' reply	67
US lawmakers call on Biden Administration to lower the price of enzalutamide	67
Radiotherapy for children and adolescents with early-stage classical Hodgkin lymphoma – Authors' reply	66
Impact of integrated palliative care in acute and aggressive medical care for patients with advanced haematological malignancies: a retrospective matched case-control study	65
Sintilimab plus IBI305 for hepatocellular carcinoma	64
Medical imaging and nuclear medicine: points to note	64
Nivolumab and sorafenib in hepatocellular carcinoma: lessons from the CheckMate 459 study	64
Enfortumab vedotin for cisplatin-ineligible urothelial cancer	64
GAIA/CLL13 provides further insight on venetoclax use in chronic lymphocytic leukaemia	63
Stereotactic ablative radiotherapy for primary kidney cancer	63
Distant metastasis-free survival with adjuvant pembrolizumab for resected stage IIB or IIC melanoma	63
Omitting hemicolectomy for patients with appendiceal neuroendocrine tumours of 1–2 cm – Authors' reply	63
Anticipating the future of cancer care in Trump's America	62
Challenging cancer through poetry	62
New evidence for brain cancer risk after a single paediatric CT scan	61
American Lung Association calls for expanded insurance coverage for lung cancer screening	61
HPV vaccine roll-out in Nigeria and Bangladesh	60
18F-NaF PET–CT versus 99mTc SPECT in bone metastasis assessment – Authors' reply	59
US legislation might soon allow easier access to cancer medications	59
PSMA-PET research: addressing challenges and prospects – Authors' reply	59
Problems with catch-up HPV vaccination after resumption of proactive recommendations	59
Abemaciclib for malignant pleural mesothelioma – Authors' reply	58
Efficacy and safety of immune checkpoint inhibitors for individuals with advanced EGFR-mutated non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitors: a systematic review, meta-a	58
Essential medicines list in national cancer control plans: a secondary analysis from a global study	58
Diagnostic accuracy of risk prediction models in postmenopausal patients with suspected ovarian cancer	58
1 in 9 USA cancer diagnoses missed during 2020 COVID-19 pandemic	57
Management of locally advanced gastric cancer	57
Immunotherapy: balancing the risks and benefits	57
Sharing a personal story behind brain cancer	57
Elective upper-neck versus whole-neck irradiation of the uninvolved neck in patients with nasopharyngeal carcinoma: an open-label, non-inferiority, multicentre, randomised phase 3 trial	57
Perspectives on emerging technologies, personalised medicine, and clinical research for cancer control in Latin America and the Caribbean	56
Sharp increase in patients waiting months for urgent cancer treatment	56
Withdrawn accelerated approvals for cancer indications in the USA: what is the marketing authorisation status in the EU?	56
Mitotane: a friend or a foe before cabozantinib treatment in adrenocortical cancer?	56
Single-dose carboplatin followed by involved-node radiotherapy for stage IIA and stage IIB seminoma (SAKK 01/10): a single-arm, multicentre, phase 2 trial	56
Cancer care and outreach in the South Asian Association for Regional Cooperation (SAARC) region: overcoming barriers and addressing challenges	55
Best practices and novel approaches for the preclinical development of drug–radiotherapy combinations for cancer treatment	55
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, op	54
The changing global landscape of national cancer control plans	54
Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-02	53
Palliative radiotherapy versus best supportive care in patients with painful hepatic cancer (CCTG HE1): a multicentre, open-label, randomised, controlled, phase 3 study	53
Essential medicines for childhood cancer in Europe: a pan-European, systematic analysis by SIOPE	53
Use of chemotherapy in patients with oesophageal, stomach, colon, rectal, liver, pancreatic, lung, and ovarian cancer: an International Cancer Benchmarking Partnership (ICBP) population-based study	53
Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised	53
Capmatinib in MET exon 14-mutated non-small-cell lung cancer: final results from the open-label, phase 2 GEOMETRY mono-1 trial	53
Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial	53
Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial	52
Thank you to The Lancet Oncology's reviewers in 2022	52
Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study	52
The Global Breast Cancer Initiative: a strategic collaboration to strengthen health care for non-communicable diseases	52
Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim resul	52
Real-time fluorescence imaging for cancer surgery: a pathologist's perspective	51
Cancer in sub-Saharan Africa: key research and action gaps	51
Secondary prevention of anthracycline cardiotoxicity in childhood cancer survivors	51
Thoracic CT follow-up after non-small-cell lung cancer resection	51
Improved cancer coverage for firefighters in Western Australia	51
Combination chemo-immunotherapy in advanced oesophageal squamous cell carcinoma	50
Indonesia and the Philippines take steps to control cancer	50
Combination therapy with olaparib and abiraterone acetate for metastatic castration-resistant prostate cancer	49
Transforming Canada's role in global cancer control	49
FDA decisions on new oncological drugs	48
Place of death of people with cancer in 12 Latin American countries: a total population study using national death registers	48
Gauging the quality-of-life benefits of immunotherapy in hepatocellular carcinoma	48
Cancer and premature mortality—pushing the frontiers of cancer care	47
Trastuzumab deruxtecan in HER2-positive metastatic colorectal cancer: less is more?	47
Losing my brother, finding myself	47
Enhancing equity and long-term impact assessments in radiotherapy environmental studies	46
Horizon 2020 evaluation highlights benefit of cross-border research but points to areas for improvement	46
Review of the monarchE trial suggests no evidence to support use of adjuvant abemaciclib in women with breast cancer – Authors' reply	46
Treatment of Richter transformation—immunotherapy to the rescue?	46